Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma

被引：0

作者：

Kumar, Shaji ^{[1
]}

Kaufman, Jonathan L. ^{[2
]}

Mikhael, Joseph ^{[3
]}

Gasparetto, Cristina ^{[4
]}

Vij, Ravi ^{[5
]}

Pegourie, Brigitte ^{[6
]}

Benboubker, Lofti ^{[7
]}

Facon, Thierry ^{[8
]}

Moreau, Philippe ^{[9
]}

Amiot, Martine ^{[10
]}

Alzate, Stefanie ^{[11
]}

Dunbar, Martin ^{[11
]}

Xu, Tu ^{[11
]}

Agarwal, Suresh ^{[11
]}

Leverson, Joel ^{[11
]}

Ross, Jeremy ^{[11
]}

Maciag, Paulo ^{[11
]}

Verdugo, Maria ^{[11
]}

Touzeau, Cyrille ^{[12
]}

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[3] Mayo Clin, Scottsdale, AZ USA

[4] Duke Univ, Hematol Malignancies & Cellular Therapy, Durham, NC 27706 USA

[5] Washington Univ, Sch Med, St Louis, MO 63110 USA

[6] CHU, Paris, France

[7] CHRU Hop Bretonneau, Paris, France

[8] Hop Claude Huriez, Serv Malad Sang, Lille, France

[9] Univ Hosp Hotel Dieu, Nantes, France

[10] CHU Nantes, Nantes, France

[11] AbbVie Inc, N Chicago, IL USA

[12] CHU Nantes, Nantes, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 01期

关键词：

D O I：

10.1016/j.clml.2017.03.046

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OP-045

引用

页码：E27 / E27

页数：1

共 50 条

[21] Safety and Efficacy of Venetoclax Salvage Therapy in Relapsed/Refractory Multiple Myeloma with and without t(11;14)
Steinhardt, Maximilian J.
Bittrich, Max
Zhou, Xiang
Noderer, Julia
Riedhammer, Christine
Xiao, Xianghui
Gawlas, Sophia
Weis, Philipp
Eisele, Florian
Munawar, Umair
Han, Seungbin
Mersi, Julia
Waldschmidt, Johannes M.
Einsele, Hermann
Rasche, Leo
Kortuem, K. Martin
BLOOD, 2023, 142
[22] Correlative biomarkers of response to venetoclax monotherapy in patients with relapsed/refractory multiple myeloma
Ross, Jeremy
Chyla, Brenda
Goswami, Rasna
Roberts-Rapp, Lisa
Sun, Yan
Jiang, Yanwen
Punnoose, Elizabeth
Verdugo, Maria
Bhathena, Anahita
Maciag, Paulo
CANCER RESEARCH, 2017, 77
[23] LENALIDOMIDE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Okada, K.
Okamoto, Y.
Tsukamoto, T.
Sugiura, H.
Matsui, H.
Ueda, T.
Jo, T.
Onishi, T.
Kunitomi, A.
Ueda, Y.
ANNALS OF ONCOLOGY, 2013, 24
[24] NK cell therapy in relapsed refractory multiple myeloma
Roshandel, Elham
Ghaffari-Nazari, Haniyeh
Mohammadian, Mozhdeh
Salimi, Maryam
Abroun, Saeid
Mirfakhraie, Reza
Hajifathali, Abbas
CLINICAL IMMUNOLOGY, 2023, 246
[25] Bendamustine therapy for advanced relapsed/refractory multiple myeloma
Shkury, Eden
Geva, Mika
Avigdor, Abraham
Nevo, Lee
Magen, Hila
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S189 - S189
[26] Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
Xiaohui Gao
Hui Zeng
Xiaoyan Zhao
Haibing Wu
Minchao Yan
Yuan Li
Gang Zhang
Fei Sun
BMC Cancer, 23
[27] A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma
Kambhampati, Swetha
Galligan, Derek
Ledergor, Guy
Martin, Thomas G., III
Wolf, Jeffrey
Wong, Sandy W.
Shah, Nina D.
BLOOD, 2019, 134
[28] Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Moreau, Philippe
Chanan-Khan, Asher Alban Akmal
Roberts, Andrew Warwick
Agarwal, Amit
Facon, Thierry
Kumar, Shaji
Touzeau, Cyrille
Diehl, Susan
Cordero, Jaclyn
Ross, Jeremy A.
Munasinghe, Wijith
Zhu, Ming
Salem, Ahmed H.
Leverson, Joel
Maciag, Paulo Cesar
Verdugo, Maria E.
Harrison, Simon J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[29] A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma
Kambhampati, Swetha
Galligan, Derek
Shah, Nina
Wolf, Jeffrey
Wong, Sandy
Martin, Thomas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E261 - E261
[30] A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma
Kambhampati, Swetha
Galligan, Derek
Huang, Chiung-Yu
Wong, Sandy
Wolf, Jeffrey
Martin, Thomas
Shah, Nina
LEUKEMIA & LYMPHOMA, 2020, 61 (05) : 1211 - 1219

← 1 2 3 4 5 →